EU Approves Enhertu-Pertuzumab in First-Line HER2-Positive Breast Cancer
The European Commission approved trastuzumab deruxtecan plus pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. In DESTINY-Breast09, the regimen reduced progression or death by 44% versus taxane, trastuzumab and…
